SWOG clinical trial number
E2998
A Phase III Study of Flt3 Ligand (Flt3L) (NSC #696599) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission
Closed
Phase
Research committees
Leukemia
Eligibility Criteria Expand/Collapse
Must have morphologic proof of AML (M0-M7 or RAEB-T) and be in >/= 2nd CR, >/= 18 years of age, ECOG performance status of 0 2; patients must be registered and started on treatment within 4 weeks of documentation of CR following induction therapy or within 4 weeks of discharge from hospital following post-remission therapy; no prior immunotherapy or allogeneic transplant; no uncontrolled or active autoimmune disease, no active cardiac or pulmonary disease.
Other Clinical Trials
SWOG Clinical Trial Number
S2507
A Phase II Randomized Study of Blinatumomab with or without Revumenib for Patients with KMT2A Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/ Acute Leukemia With Ambiguous Lineage (ALAL) with Persistent Measurable Residual Disease (MRD)
Research Committee(s)
Leukemia
Other
Activated
09/22/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2504
A Randomized Phase III Study of PIRtobrutinib plus R-CHOP vs. R-CHOP for Patients with Previously UntreateD RIchter TrAnsforMation (RT) (pirAMID)
Research Committee(s)
Leukemia
Lymphoma
Activated
06/01/2026
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/A042302
Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Research Committee(s)
Leukemia
Activated
03/06/2026
Open
Phase